Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › esketamine

esketamine

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of esketamine

9 trials tracked of esketamine: 7 in phase 3 or 4 and 6 with published results. The most-cited published study has 97 citations.

9Trials tracked
7Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 2
  1. Phase 3 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide Completed · 97 cited
  2. Phase 3 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide Completed · 97 cited
  3. Phase 3 A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression Completed · 75 cited
  4. Phase 3 A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Completed · 57 cited
  5. Phase 3 A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Completed · 57 cited
  6. Phase 3 A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Completed · 18 cited
Show 3 more trials
  1. Phase 4 A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment Completed
  2. Phase 2 Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide Completed
  3. Phase 2 A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Esketamine significantly reduces postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92) in adult patients
Rheumatology Meta-analysis
Esketamine significantly reduces postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92) in adult patients Esketamine reduces anxiety and depression after surgery
This meta-analysis of 1,312 adults undergoing general anesthesia found that esketamine significantly reduced both anxiety and depression pos…
New data shows esketamine can significantly lower feelings of anxiety and depression in adults following surgery.
Frontiers Jun 12, 2026
Meta-analysis finds esketamine improves response in treatment-resistant depression with dose-dependent adverse events
Drug Pipeline Meta-analysis
Meta-analysis finds esketamine improves response in treatment-resistant depression with dose-dependent adverse events Esketamine for depression: higher dose, more side effects
This meta-analysis of 9 RCTs (1,449 patients) found that esketamine improved clinical response rates (RR=1.94) in treatment-resistant depres…
A new analysis finds esketamine helps treatment-resistant depression, but higher doses bring more nausea, dizziness, and dissociation.
Frontiers May 28, 2026
Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression in real-world settings
Psychiatry Meta-analysis
Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression in real-world settings Real-World Results Show Esketamine Cuts Depression Symptoms Fast
This systematic review and meta-analysis evaluates intranasal esketamine in adults with treatment-resistant depression across real-world set…
Depression symptoms dropped sharply and remission rates rose over three months in adults using esketamine nasal spray in routine clinics.
May 15, 2026
Esketamine vs fentanyl for pediatric tonsillectomy pain shows comparable FLACC scores
Pediatrics RCT
Esketamine vs fentanyl for pediatric tonsillectomy pain shows comparable FLACC scores Esketamine and fentanyl ease kids' tonsil pain equally after surgery
This randomized controlled trial in 54 children scheduled for tonsillectomy compared esketamine 0.5 mg·kg to fentanyl 4 μg·kg at induction.
For kids getting tonsils out, esketamine and fentanyl control pain just as well, but esketamine keeps blood pressure steadier during surgery…
Apr 23, 2026
FDA Approves Spravato (esketamine) for Treatment-Resistant Depression and Depressive Symptoms with Acute Suicidal Ideation in Adults
Psychiatry FDA Approval
FDA Approves Spravato (esketamine) for Treatment-Resistant Depression and Depressive Symptoms with Acute Suicidal Ideation in Adults The FDA approved a new nasal spray called Spravato for severe depression
The FDA approved Spravato (esketamine) for treatment-resistant depression in adults as monotherapy or with an oral antidepressant, and for d…
FDA approved a new nasal spray for severe depression when other treatments fail or when patients face acute suicidal thoughts.
FDA Apr 17, 2026
Observational study links esketamine-induced mystical experiences to depression improvement in 45 patients
Psychiatry
Observational study links esketamine-induced mystical experiences to depression improvement in 45 patients Mystical experiences during esketamine treatment linked to better depression outcomes in small study
In an observational study of 45 patients with treatment-resistant depression receiving esketamine at two centers, 58% experienced mystical e…
Patients with treatment-resistant depression who felt mystical effects from esketamine showed greater improvement, while other side effects …
medRxiv Apr 3, 2026